Delfi Diagnostics
Business Services · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
1810 Embarcadero Rd Ste 100, Palo Alto, ...Phone Number
(800) 589-2182Website
www.delfidiagnostics.comRevenue
$6.1 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
1
1
2
2
1
About Delfi Diagnostics
DELFI Diagnostics specializes in early cancer detection through its innovative Fragmentomics Platform, which utilizes advanced machine learning and next-generation sequencing to analyze cell-free DNA from liquid biopsy samples. Their flagship products include FirstLookLung for both healthcare providers and patients, as well as DELFI-TF for treatment monitoring. The company aims to serve healthcare systems, pharmaceutical partners, and patients by providing scalable and effective cancer screening solutions. With a leadership team comprising experts in genomics, AI, and cancer biology, DELFI is committed to transforming cancer care and improving patient outcomes.Explore more
Delfi Diagnostics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Delfi Diagnostics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Delfi Diagnostics has new funding data
Earning: See what the market has to say on Delfi Diagnostics recently announced quarterly report
Check if Delfi Diagnostics has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Delfi Diagnostics
Delfi Diagnostics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Delfi Diagnostics had a recent Job posting/layoffs
Product Launch: Get notified when Delfi Diagnostics launches new products
Check out if Delfi Diagnostics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Delfi Diagnostics as Masked Content
Find 3 more new buyers
Compare Similar Companies to Delfi Diagnostics
Compare insights from companies similar to Delfi Diagnostics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Delfi Diagnostics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Delfi Diagnostics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Delfi Diagnostics.
Delfi Diagnostics financials insights
Gather financial insights about Delfi Diagnostics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series A
$100M
2022
Series B
$225M
Delfi Diagnostics Tech Stack
A closer look at the technologies used by Delfi Diagnostics
See more technologies
Most Recent Scoops
Person-Based
Medical Research
Person-Based
Medical Research, Clinical Operations
Person-Based
Product Launch, Medical Research, Clinical Operations, Healthcare Technology
Person-Based
Medical Research
Person-Based
Clinical Operations, Healthcare Operations
Top Business Services Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Delfi Diagnostics
Sign Up For FreeTo access detailed company insights
DELFI Diagnostics specializes in early cancer detection through its innovative Fragmentomics Platform, which utilizes advanced machine learning and next-generation sequencing to analyze cell-free DNA from liquid biopsy samples. Their flagship products include FirstLookLung for both healthcare providers and patients, as well as DELFI-TF for treatmen... Read More
